Reading COLL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COLL free→Reading COLL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track COLL free→QuarterlyIQ Insights · COLL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Executive Vice President and Chief Commercial Officer, Executive Vice President and Chief Medical Officer — Scott Dreyer, Thomas Smith, M.D.: Two senior executives are departing their positions.
Completion of Acquisition or Disposition of Assets. As previously disclosed, on March 19, 2026, Collegium Pharmaceutical, Inc. (the “ Company ”), entered into an Equity Purchase Agreement (the “ Purchase Agreement ”) with Corium Therapeutics Holdings, LLC, a Delaware limited liability company (“ Commave Seller ”), and Corium, LLC, a Delaware limited liability company (“ Corium Seller ” and together with Commave Seller, the “ Seller Parties ”). On May 12, 2026, pursuant to the Purchase Agreeme…
Results of Operations and Financial Condition. On May 7, 2026, Collegium Pharmaceutical, Inc. (the “Company”) issued a press release announcing its financial results for the quarterly period ended March 31, 2026. The full text of the press release issued in connection with the announcement is attached hereto as Exhibit 99.1 and is being furnished, not filed, under
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.